Medication
MPDL3280A
Generic name:
Pharmacist-reviewed drug information from the RxWiki encyclopedia.
Overview
MPDL3280A is an investigational treatment for non-small cell lung cancer.
MPDL3280A belongs to a group of drugs called monoclonal antibodies. These work by interfering with a protein called PD-L1 and therefore attacks the tumor cells and helps the body's immune system fight cancer cells.
MPDL3280A is being studied by Roche.
In 2014, the US FDA granted the first breakthrough therapy designation for MPDL3280A in metastatic bladder cancer.
All information on this site is provided “as-is” for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health.